1-7 of 7
carfilzomib
Close
Sort by
Journal Articles

Evidence-Based Minireview: Does achieving MRD negativity after initial therapy improve prognosis for high-risk myeloma patients?

Surbhi Sidana, Elisabet Manasanch
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 142–147.
https://doi.org/10.1182/hematology.2019000075
Published: 2019
Journal Articles

Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients

Sergio Giralt, Eric Seifter
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 103–109.
https://doi.org/10.1182/asheducation-2018.1.103
Published: 2018
Journal Articles

Management of multiple myeloma in the relapsed/refractory patient

Pieter Sonneveld
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 508–517.
https://doi.org/10.1182/asheducation-2017.1.508
Published: 2017
Journal Articles

Sequencing of nontransplant treatments in multiple myeloma patients with active disease

Andrew J. Yee, Noopur S. Raje
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 495–503.
https://doi.org/10.1182/asheducation-2016.1.495
Published: 2016
Journal Articles

Multiple myeloma: a model for scientific and clinical progress

Jesus San Miguel
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 1–7.
https://doi.org/10.1182/asheducation-2014.1.1
Published: 2014
Journal Articles

A practical approach to relapsed multiple myeloma

Joseph R. Mikhael
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2014) 2014 (1): 262–267.
https://doi.org/10.1182/asheducation-2014.1.262
Published: 2014
Journal Articles

Novel therapies for relapsed myeloma

A. Keith Stewart
Journal: Hematology
Hematology Am Soc Hematol Educ Program (2009) 2009 (1): 578–586.
https://doi.org/10.1182/asheducation-2009.1.578
Published: 2009